Lagging Januvia weighs on Merck’s none-too-pretty first quarter

Tracy Staton Nothing spoke more loudly today of Merck's ($ MRK) current worries than its new $ 15 billion stock-buyback program. That's quite a hefty sum to dole out to shareholders. ...

Novo’s exceptional first quarter still disappoints

Eric Palmer When can a drugmaker beat earnings expectations and project a 10% boost in profits for the year and still end up disappointing investors? When that drugmaker is Novo Nordisk ...

Jury hits Takeda with $6.5M judgment in first Actos liability case

Tracy Staton Score one for the plaintiffs in Takeda Pharmaceuticals’ Actos litigation. A California jury weighed in against the drugmaker, deciding that Takeda didn’t do ...

Humira carries AbbVie in its first quarter as standalone company

Eric Palmer AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and ...
Page 7 of 7« First...34567
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS